Loading
A phase 1/2 trial of Palacaparib, Temozolomide, Trastuzumab, Trastuzumab deruxtecan and Datopotamab deruxtecan in advanced solid tumours, run by AstraZeneca, now recruiting.
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT05417594 by AstraZeneca, with 695 participants planned, started 2022-06-24 and due to reach its primary completion in 2028-02-07. Interventions recorded: AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd) and Datopotamab Deruxtecan (Dato-DXd).
Shares Datopotamab deruxtecan, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Temozolomide, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Temozolomide, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab deruxtecan, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab deruxtecan, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab deruxtecan, Trastuzumab, AstraZeneca and the tag pipeline.